Day 3 Oct 12th Veterinary

Catherine Charreyre

Developing veterinary vaccines for emerging and re-emerging diseases: gaps and requirements

  • Key considerations when launching a veterinary vaccine development programme
  • Highlighting the constraints that are enforced by national and European regulatory authorities and provide obstacles to obtaining market authorisation
  • Promising areas of development
Thierry Van Den Berg

A transboundary problem: Lumpy Skin Disease (LSD)

  • Reviewing the current spread of the disease and the role of the vectors and the environmental factors in the epidemiology of the disease
  • Addressing the vital issue of vaccination against lumpy skin disease. Is vaccination the most effective control method?
  • How can Europe effectively deal with this re-emerging challenge?
Dr Arnaud Bataille

Peste des Petits Ruminants: state of affairs and the road towards eradication

  • Review of our knowledge of PPR epidemiology and the threat of this disease to Europe
  • Recent and on-going research of major importance for the success of the eradication, notably on vaccine development
  • Major gaps in our knowledge of this disease and how those could hinder the global eradication effort

Networking Break

Prof Martin Vordermeier

Application of DIVA vaccines to address Bovine Tuberculosis in Cattle

  • Discussing progress made on optimizing the only potentially available vaccine, bacille Calmette Guérin (BCG)
  • What strategies are there to improve BCG efficacy?
  • Highlighting recent advances in DIVA development based on the detection of host cellular immune responses by blood-testing or skin-testing approaches
  • What are the next steps necessary in order to accelerate DIVA vaccine development?
Dr Peter Daszak

The Global Virome Project: Bringing an end to pandemics

  • Sharing progressive updates on the rapid response to quickly produce several effective vaccines
  • Challenges faced, steps taken to overcome these and thoughts for future emerging disease outbreaks.  

Networking Lunch

Dr Richard Mole

The quest to develop new and improved vaccines for a range of economically important livestock diseases

  • Research and data updates in line with Moredun’s veterinary vaccine research
  • Sharing information on development portfolio for vaccines for a range of endemic diseases, particularly parasitic diseases
  • Case study: Barbervax, a vaccine against Haemonchus gastrointestinal worms in sheep 
Panel discussion

Fast track licensing: rapid registration of novel vaccine platforms panel

  • Industry and regulatory perspectives
  • Addressing acceleration of the licensing and registration process for new vet tech
  • Hear from a company who has successfully registered a novel vaccine platform through fast track licensing.
  • Discussing current challenges, hurdles faced, challenges overcome and thoughts for future
Additional panellists to be confirmed shortly..
Dr Alicia Urniza, Director EU Biologicals, VMRD, Zoetis
Jean de Foucauld

Increasing availability of veterinary medicinal products through harmonisation of national regulation regarding autogeneous farm specific vaccines

  • The need to harmonise requirements and the understanding of “in the same locality”, regarding the concept of epidemiological links between farms
  • Discussing the importance of defining good practices regarding the manufacture and control of autogenous vaccines
  • Considering potential implementation strategies to incorporate harmonisation within legislative framework
Gillian Cowan

Harmonisation of registration requirements for veterinary vaccines in East Africa and a regional, time-based Mutual Recognition Procedure

  • Harmonising technical requirements
  • Development of a Mutual Recognition Procedure (MRP)
  • Implementing MRP in the East African Community

Chair’s closing remarks and close of Congress

last published: 05/Oct/17 16:46 GMT